Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study - PubMed
6 hours ago
- #Multiple Myeloma
- #CAR T-Cell Therapy
- #Second Primary Malignancy
- The study compared second primary malignancy (SPM) risk in multiple myeloma (MM) patients receiving CAR T-cell therapy versus other systemic anticancer treatments (SACTs).
- CAR T therapy showed a significantly higher risk of hematologic SPM (17.9% vs. 13.1% at 24 months), but similar risks for any SPM and solid SPM compared to other SACTs.
- Increased bone marrow examinations after CAR T therapy (47% vs. 13% at 0–3 months) may contribute to detection bias, affecting the hematologic SPM findings.
- The results were derived from a real-world dataset with a median follow-up of 11.8 months and require cautious interpretation due to potential misclassification and detection bias.
- Physicians are advised to monitor for myeloid malignancies in MM patients following CAR T therapy, and further research is recommended to confirm the association.